Capnomed GmbH
, Stuttgart Area, Germany
Dr. Ranjita Shegokar holds a Ph.D. degree in
Pharmaceutical Technology from the SNDT University, India, and has been a postdoctoral researcher in the Department of Pharmaceutics, Biopharmaceutics , and NutriCosmetics at Free University of Berlin, Germany. Since last 8 years, she is working in the pharmaceutical industry in various technical/R&D
roles. Currently, she serves as Director of Pharma Business Unit at Capnomed
GmbH, Germany. She has authored many research articles, book chapters, and
presented several research papers in conferences. She has filed multiple patent
applications in area of drug delivery and drug targeting and edited 6 books on the above themes. She received several
national and international awards for her research. Her areas of interest
include polymeric nanoparticles, nanocrystals, lipid nanoparticles (SLNs/NLCs),
nanoemulsions, and role of excipients in delivery systems.
Currently, she is developing cancer medicine
for Pressured Intraperitoneal Aerosolised Chemotherapy (PIPAC). According to
estimates of the World Health Organization (WHO), cancer is the first leading
cause of death before age 70 years, PIPAC involves the administration of
intraperitoneal chemotherapy developed by her using an innovative concept that enhances the
efficacy by taking advantage of the physical properties of gas, drug delivery
system (solution, nanoparticles, emulsion etc) and pressure.